Health ConditionsA cold sore is a type of herpes infection caused by the herpes simplex virus that affects primarily the lip. Herpes labialis (HL), also called cold sores of the lip, is an infection primarily caused by herpes simplex virus type 1 (HSV-1) and occasionally herpes simplex virus type 2 (HSV-2). Oral herpes involves the face or mouth. It may result in small blisters in groups, often called cold sores or fever blisters, or may just cause a sore throat.
Currently, an estimated 3.8 billion people under the age of 50 are infected with HSV-1, impacting approximately 70% of the world's population. Lesions affect up to 45 percent of the U.S. population. Herpes simplex is a lifelong infection. The virus may reactivate and cause periodic outbreaks, and how often it does this varies widely from person to person. Most people with oral herpes have fewer outbreaks as they get older, particularly after age 35.
Herpes labialis is a rash of the skin and mucous membranes (in particular, the lips) and is characterized by erythema and blisters that are preceded and accompanied by tingling, itching or burning pain. Symptoms typically include a burning pain followed by small blisters or sores. The first attack may also be accompanied by fever, sore throat, and enlarged lymph nodes.
Lesions classically manifest as a well-localized cluster of small vesicles along the vermilion border of the lip or adjacent skin. The vesicles subsequently rupture, ulcerate, and crust within 24 to 48 hours. Spontaneous healing occurs over seven to ten days. Symptoms associated with recurrent oral herpes infections are generally milder relative to the symptoms that arise during the primary infection.
Constitutional symptoms in cold sores, such as fever, headache, muscle aches, and swollen lymph nodes, occur due to the body's immune response to HSV infection. When the body detects HSV, the immune system activates to fight off the infection, leading to the release of various cytokines and inflammatory mediators. These cytokines, such as interleukins, tumor necrosis factor (TNF), and interferons, cause systemic symptoms like fever and muscle aches.
The viruses live in a cluster of nerve cells (ganglion) at the side of the face, known as the trigeminal ganglion. If you become infected with herpes viruses, they stay in your trigeminal ganglion for the rest of your life. For an infection to manifest, the virus must come in contact with mucosal surfaces or abraded skin. The viral replication takes place at the site of primary infection (epithelial cells), either as an intact virion or the capsid is transported in a retrograde fashion by neurons to the dorsal root ganglia, where, after another round of viral replication, latency is established.
Despite the inefficiencies of the immune system, the course of HSV-1 infection remains under strict immunological control. Specifically, HSV-1 is controlled by a CD8+ T cell response that is cytotoxic to HSV-1-infected cells, restricts acute infection, and uses noncytolytic mechanisms to suppress reactivation in the trigeminal ganglia (TG). When this CD8+ T cell response is disrupted, reactivation of latent HSV-1 occurs.
New infectious virus particles are created during reactivation in neurons. These particles move anterogradely to the skin or mucosa, generating classic herpes sores. HSV can also infect the fingers (herpetic whitlow) or skin anywhere on the body (herpes gladiatorum). Eczema herpeticum, a widespread skin infection, is a complication of HSV infection that affects people with atopic dermatitis.
The virus may potentially enter the CNS, including the brain, and produce encephalitis or meningitis in immunosuppressive patients. In addition to cold sores and genital herpes, HSV-1 can also cause viral encephalitis (brain inflammation) and has been linked to the development of Alzheimer's disease.
Once HSV-1 has entered the body, it never leaves. The virus moves from the mouth to remain latent in the central nervous system. It has been estimated that up to 90% of the adult population is infected with HSV, which lies dormant in nervous tissue until relapse is triggered by stress or immune dysfunction.
HSV-1 infection is reactivated by various pleiotropic stressors such as exposure to ultraviolet light, fever, menstruation, psychological stress, superinfection, and skin trauma. Surgical procedures such as dental or neural surgery, lip tattooing, or dermabrasion are also common triggers.
Psychological stress is consistently highlighted across the literature as a major trigger. Stress (acute, episodic acute, or chronic), fever, UV light, and heat stress increase the incidence of reactivation from latency in humans. Surprisingly, these divergent stimuli activate the glucocorticoid receptor (GR). For example, stress increases cortisol, which activates GR via a liganded mechanism. A meta-analysis found reliable positive correlations between chronic psychological stress and HSV-1 recurrence, and sunlight is considered a major and common trigger.
UV radiation acts through a distinct pathway: ultraviolet radiation damages epithelial cells on the lips and releases interleukin-1 beta, directly contributing to viral reactivation.
Hormonal factors also play a role: hormonal changes associated with menstruation are reported as triggers by a significant subset of people with recurring cold sores, likely through effects on immune regulation and possibly through changes in neuronal signaling pathways in the trigeminal ganglia.
Concurrent infections may trigger reactivation through additional mechanisms. Researchers found that while the virus can make a protein called UL12.5 to reactivate, the protein was not needed in the presence of another infection. The scientists believe this is because the infections trigger certain "sensing pathways" that act as the home security system for neurons. Detection of a pathogen alone may be sufficient to trigger the herpes virus to begin replicating, even in instances of "abortive infections."
Genetic susceptibility is also discussed: not everyone infected with HSV experiences frequent outbreaks. Some people never have symptoms despite carrying the virus, while others deal with monthly flare-ups. Research has identified genetic factors that influence cold sore susceptibility, including specific genes on chromosome 21.
Dietary inadequacy as a trigger: reactivation of this virus is triggered by psychosocial factors such as stress, febrile environment, ultraviolet light susceptibility, or specific dietary inadequacy. However, in terms of the significance of HSV-1 trigger factors, the patient's age, sex, the environment of residency, or inappropriate lifestyle affecting health such as smoking, consuming alcohol, or taking illicit drugs were less likely to contribute when compared to perceived elevated levels of stress. There were unclear occurrences in multivariate study models and cross-sectional studies, with no conclusive evidence of the apparent association between these putative risk factors and recurrent herpes labialis.
Sleep quality is increasingly recognized: sleep deprivation is documented as an immune modulator with effects on NK cell activity and cytokine production; chronic poor sleep is associated with higher recurrence frequency in observational data.
The connection between lysine and cold sores centers on its relationship with another amino acid called arginine. The herpes simplex virus requires arginine to replicate and create new viral particles. In tissue culture studies, herpes viral replication is enhanced when the arginine/lysine ratio favors arginine. However, when the arginine/lysine ratio favors lysine, viral replication is suppressed, and cytopathogenicity of HSV is inhibited.
L-lysine is an essential amino acid used in nutritional supplementation. Its application to herpes labialis is not rooted in classical herbal or ethnobotanical tradition but emerged from laboratory hypothesis and clinical investigation beginning in the 1970s and 1980s. It has since become one of the most widely self-used supplements among people with recurrent cold sores.
Ten trials tested prophylactic lysine to prevent cold sores or mouth ulcers. Two studies reported 500 mg/day to be effective for reducing lesion frequency, but neither of these were controlled or statistically tested. In contrast, two double-blind controlled trials showed no significant effect.
One study examined the efficacy of long-term prophylactic lysine supplementation. Twenty-six volunteers with a history of frequently recurring herpetic lesions completed a 12-month double-blind crossover study. The experimental group received daily oral supplements of 1,000 mg L-lysine. In most instances, members of the lysine group reported significantly fewer lesions than the control group. Similarly, those who were taken off lysine supplementation generally showed a significant increase in lesion frequency. Data from this sample population indicated that when a person's serum lysine concentration exceeded 165 nmol/mL there was a corresponding significant decrease in recurrence rate.
L-lysine supplementation appears to be ineffective for prophylaxis or treatment of herpes simplex lesions with doses of less than 1 g/day without low-arginine diets. Findings from one small double-blind, randomized, placebo-controlled trial suggest that doses in excess of 3 g/day may reduce recurrence rates and improve patients' self-reported symptoms. Longer-duration, randomized controlled studies of lysine doses exceeding 1.2 g/day are required to definitively test its role in herpes simplex prophylaxis and determine the minimum reliably effective daily dose. This literature review uncovered no convincing evidence that lysine can be used to treat active herpes simplex lesions.
A large questionnaire-based survey lends insight into self-reported use: the average dosage used was 936 mg of lysine daily. Eighty-four percent of those surveyed said that lysine supplementation prevented recurrence or decreased the frequency of herpes infection. Whereas 79% described their symptoms as severe or intolerable without lysine, only 8% used these terms when taking lysine. Without lysine, 90% indicated that healing took six to 15 days, but with lysine 83% stated that lesions healed in five days or less. However, questionnaire-based data of this kind lacks a control group and is subject to strong reporting bias.
A Cochrane review (2015) of interventions to prevent cold sores found no consistent evidence supporting lysine's efficacy as a preventive supplement. Overall, the evidence for lysine is mixed and of low-to-moderate quality; results appear dose-dependent and may require concurrent dietary arginine restriction to be effective.
A diet tilted heavily toward arginine-rich foods without enough lysine to counterbalance may shift conditions in the virus's favor. Diet is only one piece of the puzzle, and not the most powerful one. Research has shown that a combination of lysine and arginine supplementation, where the lysine content was increased to maintain a favorable ratio, showed good control of recurrent cold sores. This suggests the ratio matters more than eliminating arginine entirely.
Some studies have also shown that eating foods rich in lysine, or avoiding foods with arginine, may help to prevent cold sore outbreaks. However, more research is needed to confirm the link between diet and the herpes simplex virus. Although non-pharmaceutical approaches beginning with nutrient supplementation such as zinc, vitamin C, vitamin D, lysine, and low-arginine diets have some potential benefits in the management of HSV-1 infections, results were mostly inconsistent and unreliable.
Zinc has been used topically in folk medicine for wound healing and skin protection for centuries. Its specific application to herpes lesions follows from its established role in immune defense and tissue repair, and zinc-based topical preparations have been studied for cold sore management in the modern era.
Zinc is an essential trace element for humans and a cofactor for over 300 enzymes, including the antioxidant superoxide dismutase. Over two billion people worldwide are affected by zinc deficiency, which is well-linked to dysfunction of both humoral and cell-mediated immunity, increasing susceptibility to infection.
Zinc salts irreversibly inhibit herpes virus replication in vitro and are effective in treating herpes infections in vivo, and have been shown in a clinical trial to be an effective topical treatment for herpes labialis. Zinc salt solutions applied to herpetic lesions decrease viral load and markedly improve healing rates, relieving the symptoms of herpes as healing occurs.
In 46 participants with facial or circumoral herpes, 21-day application of a zinc oxide/glycine cream significantly reduced the duration of cold sores and severity of symptoms (blistering, soreness, itching, tingling), compared to a placebo cream.
Zinc ions have been reported to disrupt viral multiplication. However, a meta-analysis by Cunningham et al. suggested inconclusive and limited evidence of zinc oxide creams in the treatment of recurrent herpes labialis, but found it was still reliable in lowering pain threshold and symptom periods.
Vitamin D exerts similar immunomodulatory properties to zinc, and low serum levels have been shown to be coincidental with the recurrence of cold sores; additional research is needed to discover the actual mechanism. Evidence for topical zinc is preliminary to moderate; larger, more rigorous trials are needed to confirm clinical benefit.
Vitamin D is not used in classical herbal tradition for cold sores specifically, but its role in immune modulation has been recognized in nutritional and integrative medicine contexts.
The anti-HSV activity of vitamin D may be a result of its ability to increase levels of an immunologic antimicrobial peptide called cathelicidin, which has antiviral properties against HSV-1 and other viruses. The evidence for vitamin D specifically in cold sore management is currently observational and mechanistic only; no large clinical trials specifically targeting cold sore outcomes have been completed.
Ascorbic acid has a long history of use in naturopathic and folk medicine for immune support and wound healing. Its use in the context of viral infections draws on its antioxidant and immunomodulatory properties.
In one study of 50 patients with herpetic cold sores, vitamin E application to lesions, every four hours, resulted in prompt and sustained pain relief, and the lesions healed more rapidly than expected. Direct human trial evidence for oral vitamin C specifically in cold sore prevention or treatment is limited; most rationale rests on the general role of vitamin C in immune function and collagen synthesis. The evidence for vitamin C specifically in cold sore outcomes is weak and indirect.
Lemon balm (Melissa officinalis L.) is a traditional herbal medicine accepted as a mild sedative, spasmolytic, and antibacterial agent. Lemon balm is used in folk medicine for nervous complaints, lower abdominal disorders and, more recently, for treating Herpes simplex lesions. In European phytotherapy, lemon balm leaves have been used topically as a cream for cold sores; the plant is listed in relevant phytomedicine monographs.
Melissa officinalis leaves have a range of chemical constituents; of primary importance are the tannins, polyphenols, glycosides, and rosmarinic acid. Early work with tannin and polyphenol components demonstrated activity against numerous viruses, including herpes simplex. Blockade of receptors used by the herpes virus for cell adsorption prevents viral entry into the cell, thereby interfering with viral replication.
In vitro: A hydroalcoholic lemon balm leaf extract reduced HSV-2 cytotoxicity by 60% at a nontoxic concentration of 0.5 mg/mL, via inhibiting virion entry into Vero kidney cells. Similarly, a Melissa extract was found to be 80% and 96% inhibitory, respectively, of cellular attachment by acyclovir-sensitive and acyclovir-resistant HSV-1 strains.
In humans: A double-blind study of 66 patients with recurrent herpes labialis demonstrated that a lemon balm cream (leaf extract) significantly reduced symptom scores (in blistered areas), after two days of treatment, compared to a placebo cream.
A 2025 systematic review of seven RCTs encompassing 1,250 patients found that lemon balm preparations consistently reduced pain intensity and swelling, with some studies also reporting a significant decrease in lesion size compared with placebo or acyclovir. However, considerable heterogeneity in intervention protocols and outcome measures, as well as the underrepresentation of pediatric populations, limit the generalizability of these findings. Overall, evidence for topical lemon balm is moderate and consistent across multiple small RCTs, but studies are of modest size and vary in methodology.
Propolis, a resinous bee product widely used in traditional medicine, has attracted scientific interest due to its reported antiviral, anti-inflammatory, immunomodulatory, and antioxidant properties. Propolis has been used in traditional medicine across many cultures, including ancient Egypt and in European folk medicine, primarily for wound healing and infections.
When HSV-1 viral particles were pretreated with propolis hydroalcoholic (70% ethanol) extract for 1–3 hours before being added to HEp-2 cells, significant antiviral efficacy was observed at a concentration of 10 μg/mL, alone or in combination with acyclovir.
Clinical human data: A double-blind, randomized, multicentre trial with 400 patients evaluated the effect of 0.5% GH 2002 (propolis) lip cream compared with 5% acyclovir for the treatment of the vesicular stage of herpes labialis. The primary endpoint was reached after 3 days with propolis and 4 days with acyclovir, and significant differences in favor of propolis treatment were observed for the secondary parameters.
A 2026 meta-analysis synthesized these findings: treatment with propolis and/or honey was associated with quicker lesion resolution (MD: −1.87 days; 95% CI: −2.73 to −1.01; p < 0.0001) and higher healing rates by day 7 (OR: 4.71; 95% CI: 2.70–8.25; p < 0.00001).
It is noteworthy to consider utilizing propolis in conjunction with acyclovir, to synergistically suppress HSV-1/-2 recurrence over acyclovir alone. The evidence for topical propolis is moderate to strong among studied formulations, specifically the GH 2002 extract; however, propolis composition varies significantly by geographical origin, limiting generalizability.
Honey has been used in wound healing and infection management in traditional medicine across many cultures for millennia, including in ancient Egyptian, Greek, and Ayurvedic systems. Its use specifically for herpetic lesions is a more modern extension of this broad wound-healing tradition.
An open-label RCT using medical-grade kanuka honey highlighted that botanical compounds can be an alternative to acyclovir with a favorable safety profile. A large RCT cited in the literature involved 952 adults randomized to either 5% aciclovir cream or medical-grade kanuka honey/glycerine cream, applied five times daily across 76 community pharmacies in New Zealand. Propolis formulations significantly shortened the median time to lesion encrustation and complete healing compared with acyclovir, and the combined sage–rhubarb cream showed comparable efficacy to acyclovir in mean healing time. Evidence for honey is preliminary to moderate, deriving primarily from a small number of RCTs; the kanuka honey trial is among the largest natural product trials in this area.
Tea tree oil derives from traditional Australian Aboriginal medicine, where the leaves of Melaleuca alternifolia were used for their antiseptic properties. It has become widely used in Western natural health practice for topical antimicrobial and antiviral applications.
In test tubes, tea tree oil has the ability to fight both strains of herpes viruses (HSV-1 and HSV-2). There has been one small study comparing use of tea tree oil gel to placebo in those with recurrent oral herpes. The herpes lesions of those who used the tea tree oil healed more quickly than those who used placebo. Studies of larger numbers of people are necessary, however, along with studies that compare tea tree oil to medications used for herpes. Evidence remains preliminary, limited to in vitro data and one small human study; larger RCTs have not been completed.
Olive leaf has been used medicinally in Mediterranean folk traditions, including in Ayurvedic and Middle Eastern medicine, for fever, infections, and wound healing.
Olive leaf extract demonstrated a statistically significant faster improvement in symptoms and a shorter healing time compared with acyclovir in a randomized double-blind clinical trial of 66 patients with diagnosed HSV-1. Topical herbal interventions, including lemon balm, olive leaf extract, propolis, and sage-rhubarb formulations, demonstrate potential benefits in managing herpes labialis with favorable safety profiles. Evidence is preliminary; based on a single small RCT, replication is needed.
Both sage and rhubarb root have long histories in European and Asian traditional medicine as anti-inflammatory, antimicrobial, and astringent agents. Their combination for herpes labialis is a more recent phytotherapeutic development.
The combined sage–rhubarb cream showed comparable efficacy to acyclovir in mean healing time in a study included in a 2025 systematic review of herbal interventions for herpes labialis. This evidence is limited but positive, requiring further large-scale replication.
A comprehensive review provided evidence regarding numerous natural medicaments, such as L-lysine, lemon balm (Melissa officinalis), aloe vera extract, astragalus, bee propolis, elderberry, echinacea, cat's claw, sage-rhubarb, sandalwood, tea tree oil, and witch hazel, in preventing illnesses and alleviating diseases. The evidence bases for these agents vary widely; most exist only at the level of in vitro data, traditional use, or single small clinical studies. Echinacea purpurea (800 mg of extract, plant 95% and root 5%) was found not to be useful in at least one controlled study. Although the emergence of other natural remedies showed encouraging results in some clinical trials, most did not provide complete safety profiles or were assumed to be safe due to their natural identity.
For combination products, one study using a herbal-based ointment consisting of lysine combined with ingredients such as zinc oxide, echinacea, and goldenseal found complete resolution of herpes labialis outbreaks by day three in 40% of participants. This was an open-label pilot study with limited controls, and evidence is therefore weak.
Reactivation of HSV is triggered by psychosocial factors such as stress, febrile environment, ultraviolet light susceptibility, or specific dietary inadequacy. Cold sores are caused by the herpes simplex virus, usually HSV-1. There is little to no evidence that specific foods trigger outbreaks. Nonetheless, the lysine-to-arginine dietary ratio is a frequently discussed concept. Diet may play a supporting role, but the research is not conclusive. Consuming lysine-rich foods, limiting arginine-rich foods, and focusing on immune-supporting nutrients like antioxidants, vitamin C, zinc, B vitamins, and probiotics may help.
Although non-pharmaceutical approaches beginning with nutrient supplementation such as zinc, vitamin C, vitamin D, lysine, and low-arginine diets have some potential benefits in the management of HSV-1 infections, results were mostly inconsistent and unreliable. The broader nutritional context—adequate micronutrient intake to support immune competence—is discussed more robustly in the literature than specific anti-HSV dietary prescriptions.
Excessive alcohol suppresses immune function. Heavy drinking is linked to more frequent outbreaks. This association is consistent with the general literature on alcohol and immune suppression, though direct controlled studies specific to cold sore frequency are limited.
UV light induces glucocorticoid receptor phosphorylation and transcriptional activation via ligand-independent mechanisms. UVB and UVC light, but not UVA, increase cortisol production in human skin cultures, and UVB light increases corticosteroid production. Both the direct cellular mechanism and the cortisol-mediated pathway link UV exposure to reactivation, making sun protection relevant to recurrence management.
Sleep is when the immune system performs much of its regulatory maintenance — cytokine secretion, T-cell proliferation, natural killer cell replenishment. Chronic sleep deprivation of even modest magnitude measurably reduces NK cell activity and alters cytokine profiles. This relationship between sleep and immune surveillance is mechanistically plausible but has not been tested in large prospective cold sore studies.
Stress (acute, episodic acute, or chronic), fever, UV light, and heat stress increase the incidence of reactivation from latency in humans. This is one of the most robustly supported environmental associations in the cold sore literature, supported by both observational data and mechanistic studies involving the glucocorticoid receptor and cortisol pathway.
Acemannan, the principal sulfated polysaccharide of Aloe vera, demonstrates direct inhibitory effects against HSV-1 in vitro by interfering with viral attachment to host cell glycosaminoglycans. It also promotes wound healing via fibroblast stimulation. It is considered the primary bioactive contributing to aloe vera's documented anti-HSV activity.
Aloe vera has antiviral, anti-inflammatory, and wound-healing properties documented in laboratory, animal, and limited clinical studies for herpes infections. Compounds including acemannan inhibit HSV-1 replication. A double-blind RCT (Phytomedicine 1999) found 0.5% aloe extract cream improved healing in genital herpes. Animal studies confirmed delayed blister progression in HSV lesions. Evidence for herpes labialis specifically is more limited than for genital herpes.
Bee propolis has been evaluated in multiple RCTs for herpes labialis and shown to be at least equivalent, and in several trials superior, to topical acyclovir 5% cream in reducing healing time and symptom scores. A 2026 meta-analysis confirmed propolis and honey showed better healing outcomes than acyclovir. The most studied formulation is propolis special extract GH 2002 at 0.5% concentration.
Docosanol (n-docosanol, 1-docosanol) is the only FDA-approved non-prescription topical agent for cold sores (herpes labialis). A multicenter randomized placebo-controlled trial demonstrated that 10% docosanol cream reduced mean healing time from 7.3 to 5.7 days compared to placebo. It acts by incorporating into host cell plasma membranes to block viral fusion and entry, a mechanism distinct from nucleoside analog antivirals.
Glycyrrhetinic acid, the aglycone metabolite of glycyrrhizin from licorice root, directly inhibits HSV replication and inactivates HSV particles. Anti-inflammatory mechanisms via inhibition of lipoxygenase, cyclooxygenase, and protein kinase C reduce lesion-associated inflammation. Its derivative carbenoxolone has documented clinical effectiveness specifically against recurrent herpes labialis.
Glycyrrhizin, the principal triterpenoid of licorice root, inhibits HSV replication, irreversibly inactivates herpes virus particles in vitro, and in vivo increased survival rates of HSV-1-infected mice by over 2-fold. Limited clinical evidence supports topical glycyrrhizin-containing preparations for herpes labialis; its derivative carbenoxolone has documented clinical efficacy against recurrent herpes labialis.
Medical-grade honey (kanuka, manuka) has been evaluated in clinical RCTs for herpes labialis. A large RCT (BMJ Open 2019, n=952) found kanuka honey was as effective as topical acyclovir. A clinical study found medical-grade honey (L-Mesitran) outperformed conventional cold sore treatments in healing time and symptom relief. A 2026 meta-analysis confirmed honey alongside propolis showed superior healing to acyclovir.
L-lysine is among the most researched natural agents for cold sore prevention. Multiple double-blind RCTs demonstrate that doses ≥1 g/day significantly reduce recurrence frequency and severity of herpes simplex labialis. The mechanism involves competitive antagonism of arginine, which HSV-1 requires for replication.
Lactoferrin, a glycoprotein in milk and secretions, inhibits HSV-1 infection by competing with viral glycoprotein C for cell-surface heparan sulfate binding sites, blocking the initial adsorption step. This mechanism was confirmed in PubMed-indexed mechanistic studies using GAG-deficient cell lines. It is identified among natural products with anti-HSV evidence in a 2023 narrative review.
Lemon balm (Melissa officinalis) is the most extensively studied herbal treatment for cold sores. Multiple double-blind, placebo-controlled RCTs demonstrate that topical 1% standardized lemon balm cream significantly reduces healing time, lesion size, blister count, and symptom severity. A 2025 systematic review confirmed lemon balm as among topical herbal interventions with demonstrated benefits for herpes labialis.
Glycyrrhizin and glycyrrhetinic acid demonstrate direct antiviral activity against herpes simplex virus (HSV-1/2) in in vitro and animal studies. Human clinical studies of IV glycyrrhizin for herpes family viruses (including shingles/VZV and Kaposi's sarcoma-associated herpesvirus in hepatitis B patients) showed symptom improvement. Topical glycyrrhetinic acid preparations are used for herpes/cold sores in several European countries.
Melaleuca alternifolia essential oil (tea tree oil) has documented in vitro antiherpetic activity against HSV-1 and HSV-2 via direct virucidal action before cell adsorption. Small clinical observations support reduction in cold sore healing time. It is included within the scope of herbal interventions reviewed in the 2025 systematic review of herbal medicine for herpes labialis.
Monolaurin (glycerol monolaurate), derived from lauric acid, disrupts lipid membranes of enveloped viruses including HSV-1 and HSV-2, inactivating viral particles in vitro. Laboratory studies confirm monolaurin inactivates HSV in cell cultures by interfering with viral envelope integrity. A PMC-published literature review confirmed in vitro antiviral activity against HSV; human RCTs for herpes labialis are lacking.
A randomized double-blind clinical trial comparing 2% topical OLE cream versus 5% acyclovir cream for HSV-1 labialis found OLE superior in healing time and symptom resolution. Oleuropein inhibits HSV-1 replication in vitro by stimulating PKR phosphorylation. This represents the strongest direct clinical evidence for OLE in cold sores.
Propolis is a resinous bee product with multiple RCTs demonstrating efficacy against herpes labialis at least equivalent, and often superior, to acyclovir 5% cream. A 2025 systematic review and a 2026 meta-analysis confirmed propolis as one of the strongest herbal interventions for herpes labialis, with demonstrated shorter healing times and better symptom resolution compared to acyclovir in several trials.
Quercetin demonstrates significant anti-HSV-1 activity in vitro via suppression of TLR-3-dependent inflammatory signaling and inhibition of HSV proteins (gD, ICP0) and viral genes (ICP0, UL13, UL52). It is identified as an AMPK activator with anti-HSV activity similar to resveratrol in cell culture. Evidence is primarily in vitro; no large clinical trials specific to herpes labialis have been published.
Resveratrol has been comprehensively reviewed as an anti-HSV nutraceutical agent. Multiple in vitro studies demonstrate marked inhibition of HSV-1 and HSV-2 replication via AMPK activation and NF-κB suppression. It showed activity against acyclovir-resistant HSV strains. A 2018 PMC review synthesized available evidence for its mechanisms and anti-HSV efficacy.
A double-blind, comparative randomized trial in 149 patients found that topical rhubarb-sage cream was as effective as acyclovir cream for herpes labialis (oral cold sores), with mean healing time of 6.7 days versus 6.5 days for acyclovir. The combination is superior to sage cream alone.
Tea tree oil (Melaleuca alternifolia) demonstrates significant in vitro antiherpetic activity against HSV-1 and HSV-2, primarily via direct virucidal action before host cell adsorption, confirmed in plaque reduction assays. Small clinical observations document reduction of cold sore duration from ~7 days to ~3 days with topical application. It is recognized in herbal medicine literature for antiviral activity against herpesviruses.
Vitamin C (ascorbic acid) has documented antiviral activity against HSV-1 in vitro and small clinical evidence supporting reduction of cold sore healing time as a topical paste. It is combined with vitamin E and honey in medical-grade formulations (L-Mesitran) shown in a clinical study to outperform conventional cold sore treatments. It is identified in the Viruses 2023 narrative review among natural products with evidence for controlling HSV.
Vitamin E has clinical documentation for topical cold sore pain relief and accelerated healing. A clinical case series found near-immediate pain relief and markedly accelerated healing with topical vitamin E oil applied to cold sores. Incorporated into medical-grade honey formulations (L-Mesitran), it is part of a combination shown in a clinical study to outperform conventional cold sore treatments. A 2023 narrative review identifies it among natural products with HSV evidence.
Topical zinc formulations (zinc oxide, zinc sulfate) have been evaluated in multiple RCTs and shown to modestly reduce the duration and severity of cold sore outbreaks. Zinc salts applied to herpes lesions decrease viral load and improve healing rates. Zinc gluconate is listed in the US Homeopathic Pharmacopoeia with an OTC indication for cold sores, and topical zinc oxide is referenced in authoritative cold sore treatment reviews.
Go back